| Literature DB >> 24831003 |
Yaoyu Chen1, Jinyun Chen1, Jianjun Yu2, Guizhi Yang1, Emilia Temple3, Fred Harbinski3, Hui Gao1, Christopher Wilson4, Raymond Pagliarini1, Wenlai Zhou5.
Abstract
Heat shock protein 90 (HSP90) inhibition inhibits cancer cell proliferation through depleting client oncoproteins and shutting down multiple oncogenic pathways. Therefore, it is an attractive strategy for targeting human cancers. Several HSP90 inhibitors, including AUY922 and STA9090, show promising effects in clinical trials. However, the efficacy of HSP90 inhibitors may be limited by heat shock factor 1 (HSF1)-mediated feedback mechanisms. Here, we identify, through an siRNA screen, that the histone H3 lysine 4 methyltransferase MLL1 functions as a coactivator of HSF1 in response to HSP90 inhibition. MLL1 is recruited to the promoters of HSF1 target genes and regulates their expression in response to HSP90 inhibition. In addition, a striking combination effect is observed when MLL1 depletion is combined with HSP90 inhibition in various human cancer cell lines and tumor models. Thus, targeting MLL1 may block a HSF1-mediated feedback mechanism induced by HSP90 inhibition and provide a new avenue to enhance HSP90 inhibitor activity in human cancers.Entities:
Keywords: Anticancer Drug; Heat Shock Factor 1 (HSF1); Heat Shock Protein 90 (HSP90); Tumor Cell Biology; Tumor Therapy
Mesh:
Substances:
Year: 2014 PMID: 24831003 PMCID: PMC4081932 DOI: 10.1074/jbc.M114.574053
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157